Compare Hims and Hers Health Inc (HIMS) vs Quantumscape Corp (QS) Price & Performance

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.

QuantumScape (QS) trades at $4.545, up 0.55% on the day, but remains in a bearish technical trend with significant fundamental challenges. The company continues to operate without revenue while reporting substantial losses (-$435.05M net income in 2025). Recent earnings show mixed results with two beats and one miss in the last four quarters. The stock faces headwinds from delayed commercialization timelines and insider selling activity, though institutional interest persists with Bank of New York Mellon establishing a new position.

QS represents a high-risk, speculative investment opportunity in solid-state battery technology. The primary opportunity lies in potential commercialization success with automotive partners like Volkswagen, while major risks include continued cash burn, competitive threats, and execution delays. Analyst consensus remains cautious with 73% hold ratings and a $10.35 price target suggesting 128% upside from current levels, but the path to profitability remains uncertain.